{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T23:54:41Z","timestamp":1793922881676,"version":"4.8.0"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T00:00:00Z","timestamp":1591142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Novartis Healthcare A\/S"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Calcitonin gene-related peptide (CGRP) has recently been implicated in the pathogenesis of post-traumatic headache (PTH), which raises the prospect for therapeutic use of monoclonal antibodies targeting CGRP or its receptor. Therefore, we decided to assess the efficacy, tolerability, and safety of erenumab for prevention of persistent PTH attributed to mild traumatic brain injury.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A single-center, non-randomized, single-arm, open-label study of erenumab for adults aged 18\u201365\u2009years with persistent PTH. Patients were assigned to receive 140-mg erenumab monthly by two subcutaneous 1-mL injections, given every 4\u2009weeks for 12\u2009weeks. The primary outcome measure was the mean change in number of monthly headache days of moderate to severe intensity from baseline (4-week pretreatment period) to week 9 through 12. Tolerability and safety endpoints were adverse events (i.e. number and type).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eighty-nine of 100 patients completed the open-label trial. At baseline, the mean monthly number of headache days of moderate to severe intensity was 15.7. By week 9 through 12, the number was reduced by 2.8\u2009days. The most common adverse events were constipation (n\u2009=\u200930) and injection-site reactions (n\u2009=\u200915). Of 100 patients who received at least one dose of erenumab, two patients discontinued the treatment regimen due to adverse events.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Among patients with persistent PTH, erenumab resulted in a lower frequency of moderate to severe headache days in this 12-week open-label trial. In addition, erenumab was well-tolerated as discontinuations due to adverse events were low. Placebo-controlled randomized clinical trials are needed to adequately evaluate the efficacy and safety of erenumab in patients with\u00a0persistent PTH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration<\/jats:title>\n                    <jats:p>\n                      ClinicalTrials.Gov,\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03974360\">NCT03974360<\/jats:ext-link>\n                      . Registered on April 17, 2019 - Retrospectively registered\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s10194-020-01136-z","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T10:51:45Z","timestamp":1591181505000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":80,"title":["Efficacy, tolerability, and safety of erenumab for the preventive treatment of persistent post-traumatic headache attributed to mild traumatic brain injury: an open-label study"],"prefix":"10.1186","volume":"21","author":[{"given":"H\u00e5kan","family":"Ashina","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Afrim","family":"Iljazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haidar Muhsen","family":"Al-Khazali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Kristina","family":"Eigenbrodt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eigil Lindekilde","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalie Middelboe","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin John","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karoline Bendix","family":"Br\u00e4uner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"M\u00f8rch-Jessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basit","family":"Chaudhry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Antic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Casper Emil","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Messoud","family":"Ashina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faisal Mohammad","family":"Amin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik Winther","family":"Schytz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,3]]},"reference":[{"issue":"6","key":"1136_CR1","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1001\/jama.300.6.711","volume":"300","author":"DE Nampiaparampil","year":"2008","unstructured":"Nampiaparampil DE (2008) Prevalence of chronic pain after traumatic brain injury: a systematic review. JAMA 300(6):711\u2013719","journal-title":"JAMA"},{"issue":"7","key":"1136_CR2","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1016\/S1474-4422(17)30117-5","volume":"16","author":"J van der Naalt","year":"2017","unstructured":"van der Naalt J, Timmerman ME, de Koning ME, van der Horn HJ, Scheenen ME, Jacobs B et al (2017) Early predictors of outcome after mild traumatic brain injury (UPFRONT): an observational cohort study. Lancet Neurol 16(7):532\u2013540","journal-title":"Lancet Neurol"},{"issue":"6","key":"1136_CR3","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1212\/WNL.42.6.1225","volume":"42","author":"BK Rasmussen","year":"1992","unstructured":"Rasmussen BK, Olesen J (1992) Symptomatic and nonsymptomatic headaches in a general population. Neurology 42(6):1225\u20131231","journal-title":"Neurology"},{"issue":"10","key":"1136_CR4","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1038\/s41582-019-0243-8","volume":"15","author":"H Ashina","year":"2019","unstructured":"Ashina H, Porreca F, Anderson T, Amin FM, Ashina M, Schytz HW et al (2019) Post-traumatic headache: epidemiology and pathophysiological insights. Nat Rev Neurol 15(10):607\u2013617","journal-title":"Nat Rev Neurol"},{"issue":"1","key":"1136_CR5","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1186\/s10194-019-1051-7","volume":"20","author":"EL Larsen","year":"2019","unstructured":"Larsen EL, Ashina H, Iljazi A, Al-Khazali HM, Seem K, Ashina M et al (2019) Acute and preventive pharmacological treatment of post-traumatic headache: a systematic review. J Headache Pain 20(1):98","journal-title":"J Headache Pain"},{"key":"1136_CR6","doi-asserted-by":"crossref","unstructured":"Ashina H, Iljazi A, Al-Khazali HM, Ashina S, Jensen RH, Amin FM, et al (2020) Persistent post-traumatic headache attributed to mild traumatic brain injury: deep phenotyping and treatment patterns. Cephalalgia 40(6):554\u201364","DOI":"10.1177\/0333102420909865"},{"issue":"22","key":"1136_CR7","doi-asserted-by":"publisher","first-page":"2123","DOI":"10.1056\/NEJMoa1705848","volume":"377","author":"PJ Goadsby","year":"2017","unstructured":"Goadsby PJ, Reuter U, Hallstr\u00f6m Y, Broessner G, Bonner JH, Zhang F et al (2017) A controlled trial of Erenumab for episodic migraine. N Engl J Med 377(22):2123\u20132132","journal-title":"N Engl J Med"},{"issue":"22","key":"1136_CR8","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"9","key":"1136_CR9","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of Galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"3","key":"1136_CR10","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1177\/0333102420905132","volume":"40","author":"M Ashina","year":"2020","unstructured":"Ashina M, Saper J, Cady R, Schaeffler BA, Biondi DM, Hirman J et al (2020) Eptinezumab in episodic migraine: a randomized, double-blind, placebo-controlled study (PROMISE-1). Cephalalgia 40(3):241\u2013254","journal-title":"Cephalalgia"},{"issue":"10210","key":"1136_CR11","doi-asserted-by":"publisher","first-page":"1765","DOI":"10.1016\/S0140-6736(19)32504-8","volume":"394","author":"A Charles","year":"2019","unstructured":"Charles A, Pozo-Rosich P (2019) Targeting calcitonin gene-related peptide: a new era in migraine therapy. Lancet 394(10210):1765\u20131774","journal-title":"Lancet"},{"issue":"14","key":"1136_CR12","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1177\/0333102419877662","volume":"39","author":"E Navratilova","year":"2019","unstructured":"Navratilova E, Rau J, Oyarzo J, Tien J, Mackenzie K, Stratton J et al (2019) CGRP-dependent and independent mechanisms of acute and persistent post-traumatic headache following mild traumatic brain injury in mice. Cephalalgia 39(14):1762\u20131775","journal-title":"Cephalalgia"},{"issue":"2","key":"1136_CR13","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1177\/0333102416681571","volume":"38","author":"D Bree","year":"2018","unstructured":"Bree D, Levy D (2018) Development of CGRP-dependent pain and headache related Behaviours in a rat model of concussion: implications for mechanisms of post-traumatic headache. Cephalalgia 38(2):246\u2013258","journal-title":"Cephalalgia"},{"issue":"20","key":"1136_CR14","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World Medical Association","year":"2013","unstructured":"World Medical Association (2013) World medical association declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA 310(20):2191\u20132194","journal-title":"JAMA"},{"issue":"1","key":"1136_CR15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1177\/0333102417738202","volume":"38","author":"Classification Committee of the International Headache Society","year":"2018","unstructured":"Classification Committee of the International Headache Society (2018) The international classification of headache disorders (ICHD), 3rd edition. Cephalalgia 38(1):1\u2013211","journal-title":"Cephalalgia"},{"issue":"10161","key":"1136_CR16","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1016\/S0140-6736(18)32534-0","volume":"392","author":"U Reuter","year":"2018","unstructured":"Reuter U, Goadsby PJ, Lanteri-Minet M, Wen S, Hours-Zesiger P, Ferrari MD et al (2018) Efficacy and tolerability of Erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful: a randomised, double-blind, placebo-controlled, phase 3b study. Lancet 392(10161):2280\u20132287","journal-title":"Lancet"},{"issue":"7","key":"1136_CR17","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1177\/0333102419835459","volume":"39","author":"PJ Goadsby","year":"2019","unstructured":"Goadsby PJ, Paemeleire K, Broessner G, Brandes J, Klatt J, Zhang F (2019) Efficacy and safety of Erenumab (AMG334) in episodic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 39(7):817\u2013826","journal-title":"Cephalalgia"},{"issue":"10","key":"1136_CR18","doi-asserted-by":"publisher","first-page":"1611","DOI":"10.1177\/0333102418788347","volume":"38","author":"M Ashina","year":"2018","unstructured":"Ashina M, Tepper S, Brandes JL, Reuter U, Boudreau G, Dolezil D (2018) Efficacy and safety of Erenumab (AMG334) in chronic migraine patients with prior preventive treatment failure: a subgroup analysis of a randomized, double-blind, placebo-controlled study. Cephalalgia 38(10):1611\u20131621","journal-title":"Cephalalgia"},{"issue":"3","key":"1136_CR19","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1111\/head.13451","volume":"59","author":"DM Cushman","year":"2019","unstructured":"Cushman DM, Borowski L, Hansen C, Hendrick J, Bushman T, Teramoto M (2019) Gabapentin and Tricyclics in the treatment of post-concussive headache, a retrospective cohort study. Headache. 59(3):371\u2013382","journal-title":"Headache."},{"issue":"7","key":"1136_CR20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/dmcn.12152","volume":"55","author":"A Kuczynski","year":"2013","unstructured":"Kuczynski A, Crawford S, Bodell L, Dewey D, Barlow KM (2013) Characteristics of post-traumatic headaches in children following mild traumatic brain injury and their response to treatment: a prospective cohort. Dev Med Child Neurol 55(7):636\u2013641","journal-title":"Dev Med Child Neurol"},{"issue":"6","key":"1136_CR21","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1111\/j.1526-4610.2011.01909.x","volume":"51","author":"JC Erickson","year":"2011","unstructured":"Erickson JC (2011) Treatment outcomes of chronic post-traumatic headaches after mild head trauma in us soldiers: an observational study. Headache. 51(6):932\u2013944","journal-title":"Headache."}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s10194-020-01136-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01136-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,2]],"date-time":"2021-06-02T21:55:05Z","timestamp":1622670905000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01136-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,3]]},"references-count":21,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1136"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01136-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-25874\/v1","asserted-by":"object"}]},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,3]]},"assertion":[{"value":"30 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Informed written consent was obtained from each patient before conducting any study-related procedures. The study protocol was reviewed by the Regional Health Research Ethics Committee of the Capital Region of Denmark (identifier: H-18050498).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declared the following potential conflicts of interest with respect to the research, authorship and\/or publication of this article: Dr. Casper Emil Christensen has lectured and been a scientific advisor for Teva. Dr. Messoud Ashina has received personal fees from Alder BioPharmaceuticals, Allergan, Amgen, Eli Lilly, Novartis, and Teva. Dr. Messoud Ashina has been or currently is a principal investigator on clinical trials for Alder, Amgen, electroCore, Novartis, and Teva. Dr. Messoud Ashina also serves as an Associate Editor of Cephalalgia, Associate Editor of Headache, and Co-Editor of the Journal of Headache and Pain. Dr. Messoud Ashina reports research grants from Lundbeck Foundation, Novo Nordisk Foundation, and Research Foundation of the Capital Region of Denmark. Dr. Faisal Mohammad Amin has received personal fees from Eli Lilly, Novartis and Teva. Dr. Faisal Mohammad Amin is currently a principal investigator on clinical trials for Novartis and Teva. Dr. Faisal Mohammad Amin also serves as an Associate Editor of Headache Medicine. Dr. Henrik Winther Schytz has received speaking fees from Novartis and Teva. The other authors declare no conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"62"}}